Floatz logo

Therapeutic Asset Ratings

228 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Toripalimab
PD-L1 Positive
Tianjin Medical University Cancer Institute and HospitalP2CCC (53)
TRASTUZUMAB
SHR-A1811
Tianjin Medical University Cancer Institute and HospitalP2CCC (53)
Trifluridine
First-line Treatment
Tianjin Medical University Cancer Institute and HospitalP2CCC (53)
Tuvonralimab
Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and HospitalP2CCC (53)
Tuvonralimab
Neoplasm
Tianjin Medical University Cancer Institute and HospitalP2CCC (53)
Tuvonralimab
Renal Cell Carcinoma
Tianjin Medical University Cancer Institute and HospitalP2CCC (53)
Utidelone
Metastatic Malignant Neoplasm In The Brain
Tianjin Medical University Cancer Institute and HospitalP2CCC (53)
Utidelone
Malignant Solid Tumor
Tianjin Medical University Cancer Institute and HospitalP2CCC (53)
Whole Agonist-Stimulated T Cells
Non-Small Cell Lung Carcinoma
Tianjin Medical University Cancer Institute and HospitalP2CCC (53)
DALPICICLIB ISETIONATE
NSCLC
Tianjin Medical University Cancer Institute and HospitalP2CCC (52)
Gx
Pancreatic Neoplasm
Tianjin Medical University Cancer Institute and HospitalP2/3CCC (52)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Radiotherapy
Tianjin Medical University Cancer Institute and HospitalP2CCC (51)
CIS-DIAMMINEDICHLOROPLATINUM II
Neoadjuvant Therapy
Tianjin Medical University Cancer Institute and HospitalP2CCC (51)
Cmoep
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Tianjin Medical University Cancer Institute and HospitalP2CCC (51)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Radiotherapy
Tianjin Medical University Cancer Institute and HospitalP2CCC (51)
Inno-206
Radiotherapy
Tianjin Medical University Cancer Institute and HospitalP2CCC (51)
Iparomlimab
Neoadjuvant Therapy
Tianjin Medical University Cancer Institute and HospitalP2CCC (51)
METHOTREXATE
Non-Small Cell Lung Carcinoma
Tianjin Medical University Cancer Institute and HospitalP2CCC (51)
Tagitanlimab
Triple-Negative Breast Carcinoma
Tianjin Medical University Cancer Institute and HospitalP2CCC (51)
Tucidinostat
Malignant Pancreatic Neoplasm
Tianjin Medical University Cancer Institute and HospitalP2CCC (51)
Pemigatinib
Breast Cancer
Tianjin Medical University Cancer Institute and HospitalP2CCC (50)
Gecacitinib
Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and HospitalP2CCC (48)
Gtx-006
CANCER
Tianjin Medical University Cancer Institute and HospitalP2CCC (48)
Lparomlimab
Non-Small Cell Lung Carcinoma
Tianjin Medical University Cancer Institute and HospitalP2CCC (48)
L-Til Cells
Non-Small Cell Lung Carcinoma
Tianjin Medical University Cancer Institute and HospitalP2CCC (48)
Showing 151 to 175 of 228 assets
PreviousPage 7 of 10Next